...
首页> 外文期刊>Pharmacognosy Research >Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5’-diphospho-glucuronosyltransferase isoforms
【24h】

Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5’-diphospho-glucuronosyltransferase isoforms

机译:mitragynine和7-hydroxymitragynine(Mitragyna speciosa Korth的生物碱)对大鼠和人肝微粒体中4-甲基伞形酮葡萄糖醛酸化及重组人尿苷5’-二磷酸-葡萄糖醛酸转移酶同工型的影响

获取原文

摘要

Background:Glucuronidation catalyzed by uridine 5’- diphospho-glucuronosyltransferase (UGT) is a major phase II drug metabolism reaction which facilitates drug elimination. Inhibition of UGT activity can cause drug-drug interaction. Therefore, it is important to determine the inhibitory potentials of drugs on glucuronidation.Objective:The objective was to evaluate the inhibitory potentials of mitragynine, 7-hydroxymitragynine, ketamine and buprenorphine, respectively on 4-methylumbelliferone (4-MU) glucuronidation in rat liver microsomes, human liver microsomes and recombinant human UGT1A1 and UGT2B7 isoforms.Materials and Methods:The effects of the above four compounds on the formation of 4-MU glucuronide from 4-MU by rat liver microsomes, human liver microsomes, recombinant human UGT1A1 and UGT2B7 isoforms were determined using high-performance liquid chromatography with ultraviolet detection.Results:For rat liver microsomes, ketamine strongly inhibited 4-MU glucuronidation with an IC50 value of 6.21 ± 1.51 μM followed by buprenorphine with an IC50 value of 73.22 ± 1.63 μM. For human liver microsomes, buprenorphine strongly inhibited 4-MU glucuronidation with an IC50 value of 6.32 ± 1.39 μM. For human UGT1A1 isoform, 7-hydroxymitragynine strongly inhibited 4-MU glucuronidation with an IC50 value of 7.13 ± 1.16 μM. For human UGT2B7 isoform, buprenorphine strongly inhibited 4-MU glucuronidation followed by 7-hydroxymitragynine and ketamine with respective IC50 values of 5.14 ± 1.30, 26.44 ± 1.31, and 27.28 ± 1.18 μM.Conclusions:These data indicate the possibility of drug-drug interaction if 7-hydroxymitragynine, ketamine, and buprenorphine are co-administered with drugs that are UGT2B7 substrates since these three compounds showed significant inhibition on UGT2B7 activity. In addition, if 7-hydroxymitragynine is to be taken with other drugs that are highly metabolized by UGT1A1, there is a possibility of drug-drug interaction to occur.
机译:背景:尿苷5'-二磷酸-葡萄糖醛酸糖基转移酶(UGT)催化的葡萄糖醛酸化反应是主要的II期药物代谢反应,可促进药物消除。抑制UGT活性可引起药物相互作用。因此,确定药物对葡萄糖醛酸苷化的抑制潜力很重要。目的:目的评估米他宁碱,7-羟基米他宁碱,氯胺酮和丁丙诺啡对大鼠肝脏4-甲基伞形酮(4-MU)葡萄糖醛酸苷化的抑制潜力。材料和方法:以上四种化合物对大鼠肝微粒体,人肝微粒体,重组人UGT1A1和UGT2B7从4-MU形成4-MU葡萄糖醛酸的影响。结果:对于大鼠肝微粒体,氯胺酮强烈抑制4-MU葡萄糖醛酸化,IC5​​0值为6.21±1.51μM,其次是丁丙诺啡,IC50值为73.22±1.63μM。对于人肝微粒体,丁丙诺啡强烈抑制4-MU葡糖醛酸化,IC5​​0值为6.32±1.39μM。对于人UGT1A1同工型,7-羟基米角yn碱强烈抑制4-MU葡糖醛酸化,IC5​​0值为7.13±1.16μM。对于人UGT2B7亚型,丁丙诺啡强烈抑制4-MU葡糖醛酸化,其次是7-羟基mitragynine和氯胺酮,IC50值分别为5.14±1.30、26.44±1.31和27.28±1.18μM。如果7-羟基米塔吉宁,氯胺酮和丁丙诺啡与UGT2B7底物的药物共同给药,因为这三种化合物对UGT2B7的活性均具有明显的抑制作用。此外,如果将7-羟基米塔吉宁与被UGT1A1高度代谢的其他药物同时服用,则可能会发生药物-药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号